Literature DB >> 30889486

Combination of L-Arginine and L-Norvaline protects against pulmonary fibrosis progression induced by bleomycin in mice.

Lu Gao1, Jia-Hua Zhang2, Xiao-Xu Chen1, Hui-Li Ren1, Xiu-Ling Feng1, Jia-Ling Wang1, Jun-Hua Xiao3.   

Abstract

Pulmonary fibrosis (PF) progression may be involved with arginine (Arg) metabolism and immune balance. The present study aimed to explore the effects of L-Arginine (L-Arg) and L-Norvaline (L-Nor) on bleomycin (BLM)-induced PF in mice, meanwhile, and observe dynamic changes of Arg metabolism, immune balance and crosstalk between them in PF progression. Followed intratracheal instillation of BLM or saline, Kunming mice were treated orally with saline, L-Arg, L-Nor and L-Arg + L-Nor three times a day. And the mice were sacrificed on Day 3, 14 and 28 after treatment. Changes of body weight, lung index, lung hydroxyproline and histopathology were analyzed to evaluate the PF degree. Peripheral blood Arg, Citrulline (Cit), Ornithine (Orn) and Proline (Pro), lung NO, NOS and arginase were analyzed to evaluate the Arg metabolism. Peripheral blood Tregs, Th17 and γδT cells were analyzed to evaluate the immune balance. Our data showed that combination of L-Arg and L-Nor dynamically reversed the weight loss, decreased lung index and hydroxyproline, and improved lung histopathological damages induced by BLM. The combination dynamically and significantly rectified Tregs, Th17, γδT and Tregs/Th17 abnormal changes. Meanwhile, these disorders of peripheral blood Arg, Cit, Orn, Pro, Orn/Cit and Pro/Orn, and lung NO, iNOS and TNOS were also improved accordingly. These results demonstrated that combination of L-Arg and L-Nor had inhibitory effects on BLM-induced PF progression, possibly due to their corrective action on immune imbalance, Arg metabolism disorder and crosstalk abnormality in the progression of PF.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Arginine metabolism; Balance; Immune; L-Arginine; L-Norvaline; Pulmonary fibrosis

Mesh:

Substances:

Year:  2019        PMID: 30889486     DOI: 10.1016/j.biopha.2019.108768

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  Metabolic Regulation of Fibroblast Activation and Proliferation during Organ Fibrosis.

Authors:  Sudan Wang; Yan Liang; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2022-03-03

2.  Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.

Authors:  Ji-Min Li; David C Yang; Justin Oldham; Angela Linderholm; Jun Zhang; Jun Liu; Nicholas J Kenyon; Ching-Hsien Chen
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

Review 3.  Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective.

Authors:  Gonçalo S Clemente; Aren van Waarde; Inês F Antunes; Alexander Dömling; Philip H Elsinga
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

Review 4.  Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy.

Authors:  Wenjing Xu; Chunping Ye; Xin Qing; Shengli Liu; Xinyi Lv; Wenjun Wang; Xiaochen Dong; Yewei Zhang
Journal:  Mater Today Bio       Date:  2022-07-12

5.  Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis.

Authors:  Jianrong Yang; Chunxia Chen; Wan Chen; Luying Huang; Zhao Fu; Kun Ye; Liwen Lv; Zhihuang Nong; Xing Zhou; Wensheng Lu; Mei Zhong
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

Review 6.  Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis.

Authors:  Josep Mercader-Barceló; Joan Truyols-Vives; Carlos Río; Nora López-Safont; Ernest Sala-Llinàs; Alice Chaplin
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

7.  Shared and Specific Lung Microbiota with Metabolic Profiles in Bronchoalveolar Lavage Fluid Between Infectious and Inflammatory Respiratory Diseases.

Authors:  Yukun He; Wenyi Yu; Pu Ning; Qiongzhen Luo; Lili Zhao; Yu Xie; Yan Yu; Xinqian Ma; Li Chen; Yali Zheng; Zhancheng Gao
Journal:  J Inflamm Res       Date:  2022-01-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.